natgillin/translations-raw huggingface dataset:
Regular monitoring of the renal function of patients should be maintained throughout the treatment duration (see section 4.4) 
Redovito praćenje bubrežne funkcije u bolesnika treba se održavati tijekom cijelog trajanja liječenja (vidjeti dio 4.4).
EVOTAZ is a fixed-dose combination of the antiviral drug atazanavir boosted by the pharmacokinetic enhancer cobicistat. 
EVOTAZ je fiksna kombinacija antivirusnog lijeka atazanavira pojačanog farmakokinetičkim pojačivačem kobicistatom.
However, atazanavir must not be used in patients with moderate (Child-Pugh Class B) to severe (Child-Pugh Class C) hepatic impairment. 
Međutim, atazanavir se ne smije primjenjivati u bolesnika s umjerenim (Child-Pugh stadij B) do teškim (Child-Pugh stadij C) oštećenjem jetrene funkcije.
What you need to know before you take EVOTAZ 3. 
Što morate znati prije nego počnete uzimati EVOTAZ 3. Kako uzimati EVOTAZ 4. Moguće nuspojave
As EVOTAZ contains atazanavir and cobicistat, any interactions that have been identified with these active substances individually may occur with EVOTAZ. 
Budući da EVOTAZ sadrži atazanavir i kobicistat, sve interakcije identificirane kod primjene tih dviju djelatnih tvari zasebno mogu se javiti i kod primjene lijeka EVOTAZ.
Increase monitoring for adverse reactions. 
Potreban je pojačan nadzor zbog mogućih nuspojava.
Clarithromycin may increase concentrations of atazanavir and cobicistat. 
Klaritromicin može povisiti koncentracije atazanavira i kobicistata.
In some cases, nephrolithiasis has been associated with acute renal failure or renal insufficiency. 
U nekim je slučajevima nefrolitijaza bila povezana s akutnim zatajenjem bubrega ili bubrežnom insuficijencijom.
Patients receiving tenofovir disoproxil should be monitored for tenofovir-associated adverse reactions. 
Bolesnike koji primaju tenofovirdizoproksil potrebno je nadzirati zbog mogućih nuspojava povezanih s tenofovirom.
When administered in combination, no clear additive or synergistic cardiovascular effects were observed at atazanavir and cobicistat concentrations at least 2-fold higher than the free atazanavir and cobicistat concentrations at the RHD Cmax. 
Kada su se primjenjivali u kombinaciji, nisu primijećeni nikakvi očiti aditivni ni sinergistički učinci na kardiovaskularni sustav pri koncentracijama atazanavira i kobicistata koje su bile najmanje 2 puta više od koncentracija slobodnog atazanavira i kobicistata pri vrijednosti Cmax koja se postiže nakon primjene preporučene doze za ljude.
Skin and subcutaneous tissue disorders common rash uncommon pruritus, erythema multiformea,b, toxic skin eruptionsa,b, drug rash with eosinophilia and systemic symptoms (DRESS) syndromea,b, angioedemaa, urticaria, alopecia rare 
Poremećaji kože i potkožnog tkiva često osip manje često svrbež, multiformni eritema,b, toksične kožne erupcijea,b, medikamentozni osip praćen eozinofilijom i sistemskim simptomima (DRESS)a,b, angioedema, urtikarija, alopecija rijeko
Based on the very limited renal elimination of cobicistat and atazanavir, no special precautions or dose adjustments of EVOTAZ are required for patients with renal impairment. 
S obzirom na vrlo ograničenu eliminaciju kobicistata i atazanavira putem bubrega, u bolesnika s oštećenjem bubrežne funkcije nisu potrebne posebne mjere opreza ni prilagodbe doze lijeka EVOTAZ.
Cobicistat is primarily metabolised and eliminated by the liver. 
Kobicistat se metabolizira i eliminira prvenstveno putem jetre.
Film-coating hypromellose (hydroxypropyl methyl cellulose, E464) titanium dioxide (E171) talc (E553b) triacetin (E1518) red iron oxide (E172) 
Film ovojnica hipromeloza (hidroksipropilmetilceluloza, E464) titanijev dioksid (E171) talk (E553b) triacetin (E1518) željezov oksid, crveni (E172)
No teratogenic effects were observed in rats or rabbits at maternally toxic doses. 
Nisu opaženi teratogeni učinci u štakora ni kunića pri dozama koje su bile toksične za majku.
The frequency of treatment emergent hepatitis or transaminase elevations in co-infected patients was comparable between atazanavir and comparator regimens (see section 4.4). 
Učestalost hepatitisa ili povišenja razine transaminaza koji su se u bolesnika s istodobnim infekcijama javljali tijekom liječenja bila je usporediva kod primjene atazanavira i usporednih režima (vidjeti dio 4.4).
Co-administration with EVOTAZ may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5 inhibitor-associated adverse events. 
Istodobna primjena s lijekom EVOTAZ može povisiti koncentracije inhibitora PDE5 i pojačati nuspojave povezane s djelovanjem inhibitora PDE5.
In an analysis of treatment-failure subjects who received atazanavir 300 mg co-administered with cobicistat 150 mg in study GS-US-216-0114 through Week 144, evaluable genotypic data from paired baseline and treatment-failure isolates were available for all 21 virologic failures in this group (6%, 21/344). 
U analizi ispitanika koji nisu odgovorili na liječenje, a primali su atazanavir u dozi od 300 mg istodobno s kobicistatom u dozi od 150 mg tijekom 144 tjedana u ispitivanju GS-US-216-0114, ocjenjivi genotipski podaci iz uparenih izolata prikupljenih na početku ispitivanja i nakon neuspjeha liječenja bili su dostupni za svih 21 slučajeva virološkog neuspjeha u toj skupini bolesnika (6%, 21/344).
Patients with chronic hepatitis B or hepatitis C virus co-infection: 
Bolesnici s istodobnom kroničnom infekcijom virusom hepatitisa B ili hepatitisa C
There have been reports of unusual heart beat in patients taking atazanavir-containing regimen. 
Prijavljeni su i slučajevi nepravilnog srčanog ritma u bolesnika liječenih režimom koje je sadržavao atazanavir.
Cobicistat: AUC: ↔ Cmax: ↔ Cmin: ↓66% 
Kobicistat: AUC: ↔ Cmax: ↔ Cmin: ↓66%
EVOTAZ should not be initiated in patients with creatinine clearance less than 70 ml/min if one or more co-administered agent requires dose adjustment based on creatinine clearance (e.g. emtricitabine, lamivudine, tenofovir disoproxil or adefovir; see sections 4.2, 4.8 and 5.2). 
Liječenje lijekom EVOTAZ ne smije se započeti u bolesnika s klirensom kreatinina manjim od 70 ml/min ako bilo koji od istodobno primijenjenih lijekova zahtijeva prilagodbu doze na temelju klirensa kreatinina (npr. emtricitabin, lamivudin, tenofovirdizoproksil ili adefovir; vidjeti dijelove 4.2, 4.8 i 5.2).
Indinavir is associated with indirect unconjugated hyperbilirubinaemia due to inhibition of UGT. 
Indinavir se povezuje s indirektnom (nekonjugiranom) hiperbilirubinemijom zbog inhibicije UGT-a.
Co-administration of EVOTAZ with proton pump inhibitors is not recommended. 
Ne preporučuje se istodobna primjena lijeka EVOTAZ s inhibitorima protonske pumpe.
Voxilaprevir Cmax : ↑342% (↑265% 
Voksilaprevir Cmax: ↑342% (↑265%
In addition to the opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. 
Nakon što započnete liječenje HIV infekcije, osim oportunističkih infekcija mogu se pojaviti i autoimune bolesti (stanja koja nastaju kada imunosni sustav napada zdrava tjelesna tkiva).
Rifampicin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect of EVOTAZ and development of resistance to atazanavir. 
Rifampicin značajno snizuje plazmatske koncentracije atazanavira, što za posljedicu može imati gubitak terapijskog učinka lijeka EVOTAZ i razvoj rezistencije na atazanavir.
A study of the pharmacokinetics of cobicistat was performed in non-HIV-1 infected subjects with moderate hepatic impairment (Child-Pugh Class B). 
Ispitivanje farmakokinetike kobicistata provedeno je u ispitanika bez HIV-1 infekcije koji su imali umjereno oštećenje jetrene funkcije (Child-Pugh stadij B).
Co-administration with EVOTAZ may result in increased concentrations of salmeterol and an increase in salmeterol-associated adverse events. 
Istodobna primjena s lijekom EVOTAZ može povisiti koncentracije salmeterola i pojačati nuspojave povezane sa salmeterolom.
Among 1,151 patients receiving atazanavir 400 mg once daily, 177 patients were co-infected with chronic hepatitis B or C, and among 655 patients receiving atazanavir 300 mg once daily with ritonavir 100 mg once daily, 97 patients were co-infected with chronic hepatitis B or C. Co-infected patients were more likely to have baseline hepatic transaminase elevations than those without chronic viral hepatitis. 
Od 1151 bolesnika koji su primali atazanavir u dozi od 400 mg jedanput na dan, njih 177 imalo je istodobnu kroničnu infekciju virusom hepatitisa B ili C, dok je među 655 bolesnika koji su primali atazanavir u dozi od 300 mg jedanput na dan s ritonavirom u dozi od 100 mg jedanput na dan, njih 97 imalo istodobnu kroničnu infekciju virusom hepatitisa B ili C.
Ethinyloestradiol AUC: ↔ Ethinyloestradiol Cmax: ↔ Ethinyloestradiol Cmin: Not calculated 
Etinilestradiol AUC: ↔ Etinilestradiol Cmax: ↔ Etinilestradiol Cmin: Nije računato
Patients were randomised in a 1:1 ratio to receive either atazanavir 300 mg with cobicistat 150 mg once daily or atazanavir 300 mg with ritonavir 100 mg once daily, each administered with a fixed background regimen containing tenofovir DF 300 mg and emtricitabine 200 mg administered as a fixed-dose combination tablet. 
Bolesnici su bili randomizirani u omjeru 1:1 za primanje atazanavira u dozi od 300 mg u kombinaciji s kobicistatom u dozi od 150 mg jedanput na dan ili atazanavira u dozi od 300 mg u kombinaciji s ritonavirom u dozi od 100 mg jedanput na dan, oba uz fiksni osnovni režim koji je sadržavao tenofovir DF u dozi od 300 mg i emtricitabin u dozi od 200 mg, primijenjen u obliku tablete s fiksnom kombinacijom doza.
In study GS-US-216-0114, through 144 weeks of treatment hyperbilirubinaemia (> 1 x ULN) was common: 97.7% in the atazanavir boosted with cobicistat plus emtricitabine and tenofovir DF fixed-dose combination group, and 97.4% in the atazanavir boosted with ritonavir plus emtricitabine and tenofovir DF fixed-dose combination group. 
U ispitivanju GS-US-216-0114 je hiperbilirubinemija (> 1 x gornja granica normale [GGN]) tijekom 144 tjedna liječenja bila česta: javila se u 97,7% bolesnika u skupini koja je primala atazanavir pojačan kobicistatom plus fiksnu kombinaciju emtricitabina i tenofovira DF i u 97,4% bolesnika u skupini koja je primala atazanavir pojačan ritonavirom plus fiksnu kombinaciju emtricitabina i tenofovira DF.
Gastrointestinal disorders very common nausea common vomiting, diarrhoea, dyspepsia, abdominal pain, abdominal distension, flatulence, dry mouth uncommon pancreatitis, gastritis, stomatitis aphthous 
Poremećaji probavnog sustava vrlo često mučnina često povraćanje, proljev, dispepsija, bol u abdomenu, distenzija abdomena, flatulencija, suha usta manje često pankreatitis, gastritis, aftozni stomatitis
Carbamazepine Phenobarbital Phenytoin 
ANTIEPILEPTICI Karbamazepin Fenobarbital Fenitoin
These antiepileptics are expected to decrease atazanavir and/or cobicistat plasma concentrations. 
Očekuje se da će ovi antiepileptici sniziti plazmatske koncentracije atazanavira i/ili kobicistata.
No significant effect on lamivudine and zidovudine concentrations was observed when co-administered with atazanavir. 
Nije opažen značajan učinak na koncentracije lamivudina i zidovudina pri istodobnoj primjeni s atazanavirom.
Table 2: Tabulated summary of adverse reactions 
Tablica 2: Tablični prikaz nuspojava
Co-administration of EVOTAZ with other protease inhibitors is not recommended. 
Ne preporučuje se istodobna primjena lijeka EVOTAZ s drugim inhibitorima proteaze.
The active substances are atazanavir and cobicistat. 
Djelatne tvari su atazanavir i kobicistat.
Unchanged drug accounted for approximately 20% and 7% of the administered dose in the faeces and urine, respectively. 
Lijek u neizmijenjenom obliku činio je približno 20% primijenjene doze u fecesu i 7% u mokraći.
Atazanavir should be used with caution in patients with mild (Child-Pugh Class A) hepatic impairment. 
Atazanavir treba primjenjivati uz oprez u bolesnika s blagim (Child-Pugh stadij A) oštećenjem jetrene funkcije.
An increase of > 3 x ULN in alanine aminotransferase or aspartate aminotransferase was recorded in 12.8% of subjects in the cobicistat-boosted group and 9.0% in the ritonavir-boosted group. 
Porast razine alanin aminotransferaze ili aspartat aminotransferaze > 3 x GGN zabilježen je u 12,8% ispitanika u skupini koja je primala atazanavir pojačan kobicistatom i 9,0% ispitanika u skupini koja je primala atazanavir pojačan ritonavirom.
EVOTAZ should not be initiated in patients with creatinine clearance less than 70 ml/min if any co-administered agent (e.g. emtricitabine, lamivudine, tenofovir disoproxil or adefovir) requires dose adjustment based on creatinine clearance (see sections 4.4, 4.8 and 5.2). 
Liječenje lijekom EVOTAZ ne smije se započeti u bolesnika s klirensom kreatinina manjim od 70 ml/min ako bilo koji od istodobno primijenjenih lijekova (npr. emtricitabin, lamivudin, tenofovirdizoproksilili adefovir) zahtijeva prilagodbu doze na temelju klirensa kreatinina (vidjeti dijelove 4.4, 4.8 i 5.2).
There are limited clinical data with cobicistat in pregnant women. 
Klinički podaci o primjeni kobicistata u trudnica su ograničeni.
Avoid concomitant use of EVOTAZ and rivaroxaban. 
Treba izbjegavati istodobnu primjenu lijeka EVOTAZ i rivaroksabana.
Among experienced patients treated with atazanavir 300 mg once daily with 100 mg ritonavir once daily for a median duration of 95 weeks, 53% had Grade 3-4 total bilirubin elevations. 
Među prethodno liječenim bolesnicima koji su primali atazanavir u dozi od 300 mg jedanput na dan sa 100 mg ritonavira jedanput na dan tijekom medijana od 95 tjedana, njih 53% imalo je povišenje ukupnog bilirubina 3.-4. stupnja.
Tablet core microcrystalline cellulose (E460(i)) croscarmellose sodium (E468) sodium starch glycolate crospovidone (E1202) stearic acid (E570) magnesium stearate (E470b) hydroxypropyl cellulose (E463) silicon dioxide (E551) 
Jezgra tablete celuloza, mikrokristalična (E460(i)) karmelozanatrij, umrežena (E468) natrijev škroboglikolat krospovidon (E1202) stearatna kiselina (E570) magnezijev stearat (E470b) hidroksipropilceluloza (E463) silicijev dioksid (E551)
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as atazanavir, where bioavailability is limited and half-life is shortened by CYP3A-dependent metabolism. 
Inhibicijom metabolizma u kojem posreduje CYP3A, kobicistat povećava sistemsku izloženost supstratima za CYP3A (poput atazanavira), koji zbog metabolizma ovisnog o CYP3A imaju ograničenu bioraspoloživost i kratak poluvijek.
Co-administration of neuroleptics with EVOTAZ may result in increased plasma concentrations of neuroleptics. 
Istodobna primjena neuroleptika s lijekom EVOTAZ može povisiti plazmatske koncentracije neuroleptika.
Following oral administration of [14C]cobicistat, 86% and 8.2% of the dose were recovered in faeces and urine, respectively. 
Nakon peroralne primjene [14C]kobicistata, 86% doze pronađeno je u fecesu, a 8,2% u mokraći.
Because atazanavir is a component of EVOTAZ, co-administration of EVOTAZ with nevirapine or efavirenz is not recommended (see section 4.5). 
Budući da je atazanavir sastavnica lijeka EVOTAZ, ne preporučuje se istodobna primjena lijeka EVOTAZ s nevirapinom ili efavirenzom (vidjeti dio 4.5).
Telaprevir 750 mg three times daily (cobicistat 150 mg once daily in combination with elvitegravir) 
Telaprevir 750 mg triput na dan (kobicistat 150 mg jedanput na dan u kombinaciji s elvitegravirom)
Administration of a single dose of EVOTAZ with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 42% increase in atazanavir Cmax, a 28% increase in atazanavir AUC, a 31% increase in cobicistat Cmax, and a 24% increase in cobicistat AUC relative to the fasting state. 
Primjena jedne doze lijeka EVOTAZ uz lagan obrok (336 kcal, 5,1 g masnoća, 9,3 g proteina) povećala je Cmax atazanavira za 42%, AUC atazanavira za 28%, Cmax kobicistata za 31% i AUC kobicistata za 24% u odnosu na primjenu natašte.
Buprenorphine AUC: ↑35% Buprenorphine Cmax: ↑66% Buprenorphine Cmin: ↑12% 
Buprenorfin AUC: ↑35% Buprenorfin Cmax: ↑66% Buprenorfin Cmin: ↑12%
Co-administration with the following medicinal products that are strong inducers of the CYP3A4 isoform of cytochrome P450 due to the potential for loss of therapeutic effect (see section 4.5): carbamazepine, phenobarbital, phenytoin (antiepileptics) St John's wort (Hypericum perforatum) (herbal product) rifampicin (antimycobacterial) 
Istodobna primjena sa sljedećim lijekovima, koji su snažni induktori izooblika CYP3A4 citokroma P450, zbog mogućeg gubitka terapijskog učinka (vidjeti dio 4.5): karbamazepin, fenobarbital, fenitoin (antiepileptici) gospina trava (Hypericum perforatum) (biljni pripravak). rifampicin (antimikobakterijski lijek)
Co-administration of EVOTAZ with medicinal products that are strong inducers of CYP3A (such as carbamazepine, phenobarbital, phenytoin, rifampicin, and St. John's wort [Hypericum perforatum]) may result in decreased plasma concentrations of atazanavir and/or cobicistat, leading to loss of therapeutic effect and possible development of resistance to atazanavir (see section 4.3 and Table 1). 
Istodobna primjena lijeka EVOTAZ i lijekova koji su jaki induktori CYP3A (kao što su karbamazepin, fenobarbital, fenitoin, rifampicin i gospina trava [Hypericum perforatum]) može za posljedicu imati smanjene plazmatske koncentracije atazanavira i/ili kobicistata, što dovodi do gubitka terapijskog učinka i mogućeg razvoja rezistencije na atazanavir (vidjeti dio 4.3 i Tablicu 1).
Co-administration with EVOTAZ may cause a large increase in the concentration of these benzodiazepines. 
Istodobna primjena s lijekom EVOTAZ može jako povisiti koncentracije tih benzodiazepina.
Co-administration of EVOTAZ with these medicinal products is expected to substantially increase their concentrations and may result in PDE5-associated adverse reactions such as hypotension, visual changes and priapism (see section 4.5). 
Pri istodobnoj primjeni lijeka EVOTAZ i tih lijekova očekuje se znatno povećanje njihove koncentracije, što može rezultirati nuspojavama povezanima s PDE5, kao što su hipotenzija, poremećaji vida i prijapizam (vidjeti dio 4.5).
Among naïve patients treated with atazanavir 300 mg once daily with 100 mg ritonavir once daily for a median duration of 96 weeks, 48% had Grade 3-4 total bilirubin elevations (see section 4.4). 
Među bolesnicima koji prethodno nisu bili liječeni i primali su atazanavir u dozi od 300 mg jedanput na dan sa 100 mg ritonavira jedanput na dan tijekom medijana od 96 tjedana, njih 48% imalo je povišenje ukupnog bilirubina 3.-4. stupnja (vidjeti dio 4.4).
EVOTAZ must not be co-administered with colchicine to patients with renal or hepatic impairment. 
EVOTAZ se ne smije primjenjivati istodobno s kolhicinom u bolesnika s oštećenjem bubrežne ili jetrene funkcije.
In female mice, atazanavir exposure at a dose that produced single-cell necrosis was 12 times the exposure in humans given 400 mg once daily. 
U ženki miša, izloženost atazanaviru u dozi koja je izazvala nekrozu pojedinačnih stanica bila je 12 puta veća od izloženosti u ljudi koji su primali dozu od 400 mg jedanput na dan.
The use of EVOTAZ is contraindicated in patients with moderate to severe hepatic impairment. 
Primjena lijeka EVOTAZ kontraindicirana je u bolesnika s umjerenim do teškim oštećenjem jetrene funkcije.
The mechanism of interaction is inhibition of metabolism by atazanavir. 
Mehanizam interakcije je inhibicija metabolizma koju uzrokuje atazanavir.
No meaningful differences in cobicistat pharmacokinetics were observed between subjects with severe renal impairment and healthy subjects, consistent with low renal clearance of cobicistat. 
Nisu opažene značajne razlike u farmakokinetici kobicistata između ispitanika s teškim oštećenjem funkcije bubrega i zdravih ispitanika, što je u skladu s niskim stupnjem bubrežnog klirensa kobicistata.
No dose adjustment of cobicistat is required in patients with mild or moderate hepatic impairment. 
Nije potrebno prilagođavati dozu kobicistata u bolesnika s blagim ili umjerenim oštećenjem jetrene funkcije.
The mechanism of interaction is a reduced solubility of atazanavir with increasing pH related to the presence of anti-acid agent in didanosine buffered tablets. 
Mehanizam interakcije je smanjenje topljivosti atazanavira uz povećanje pH povezano s prisutnošću antacida u puferiranim tabletama didanozina.
EVOTAZ must not be used in patients with moderate to severe hepatic impairment (see section 4.3). 
EVOTAZ se ne smije primjenjivati u bolesnika s umjerenim do teškim oštećenjem jetrene funkcije (vidjeti dio 4.3).
Combinations of EVOTAZ and indinavir have not been studied and co-administration of these medicinal products is not recommended (see section 4.5). 
Kombinacije lijeka EVOTAZ i indinavira nisu ispitivane pa se njihova istodobna primjena ne preporučuje (vidjeti dio 4.5).
The effects of hepatic impairment on the pharmacokinetics of atazanavir given with cobicistat have not been studied. 
Učinci oštećenja funkcije jetre na farmakokinetiku atazanavira primijenjenog s kobicistatom nisu se ispitivali.
Unlike ritonavir, cobicistat is not an inducer of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1. 
Za razliku od ritonavira, kobicistat ne inducira CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 ni UGT1A1.
ANTIMYCOBACTERIALS 
ANTIMIKOBAKTERIJSKI
Serious skin rash, including Stevens-Johnson syndrome, may develop in patients taking EVOTAZ. 
U bolesnika koji su uzimaju EVOTAZ može se razviti ozbiljan kožni osip, uključujući StevensJohnsonov sindrom.
Concomitant use contraindicated 
Istodobna primjena koja je kontraindicirana
Atazanavir is primarily hepatically metabolised and increased plasma concentrations were observed in patients with hepatic impairment (see sections 4.2 and 5.2). 
Atazanavir se prvenstveno metabolizira u jetri, pa su u bolesnika s oštećenjem jetrene funkcije bile opažene povišene koncentracije atazanavira u plazmi (vidjeti dijelove 4.2 i 5.2).
The mechanism of interaction between efavirenz and atazanavir, or efavirenz and cobicistat is CYP3A4 induction by efavirenz. 
Mehanizam interakcije između efavirenza i atazanavira ili efavirenza i kobicistata je indukcija CYP3A4 koju uzrokuje efavirenz.
Contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecaprevir and pibrentasvir plasma concentrations (see section 4.3) 
Kontraindicirano zbog mogućeg povećanog rizika povišenja ALT-a zbog značajnog povišenja koncentracije glekaprevira i pibrentasvira u plazmi (vidjeti dio
The median baseline CD4+ cell count was 352 cells/mm3 (range: 1-1455) and 16.9% had CD4+ cell counts ≤200 cells/mm3. 
Medijan dobi ispitanika iznosio je 36 godina (raspon: Medijan početne plazmatske vrijednosti HIV-1 RNK bio je 4,81 log10 kopija/ml (raspon: The median baseline CD4+ cell count was 352 cells/mm3 (range: 1-1455) and 16.9% had CD4+ cell counts ≤200 cells/mm3.
How to store EVOTAZ 
Kako čuvati EVOTAZ
The mechanism of interaction is CYP3A induction by the antiepileptic. 
Mehanizam interakcije je indukcija CYP3A koju uzrokuje antiepileptik.
Co-administration of nevirapine and cobicistat is expected to decrease cobicistat plasma concentrations while nevirapine plasma concentrations may be increased. 
Očekuje se da će istodobna primjena nevirapina i kobicistata sniziti plazmatske koncentracije kobicistata, dok bi plazmatske koncentracije nevirapina mogle porasti.
Co-administration of EVOTAZ with medicinal products containing ritonavir or cobicistat, which are strong inhibitors of CYP3A, may result in additional boosting and increased plasma concentration of atazanavir. 
Istodobna primjena lijeka EVOTAZ i lijekova koji sadrže ritonavir ili kobicistat, koji su snažni inhibitori CYP3A, može dodatno pojačati učinak i povisiti plazmatske koncentracije atazanavira.
The antiretroviral effect of EVOTAZ is due to the atazanavir component. 
Antiretrovirusni učinak lijeka EVOTAZ posljedica je djelovanja sastavnice atazanavira.